Status:
ACTIVE_NOT_RECRUITING
Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma
Lead Sponsor:
Centre Jean Perrin
Collaborating Sponsors:
Association Nationale des Patients atteints de cancers de l'oeil (A.N.P.A.C.O.)
Conditions:
Uveal Melanoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Only 20% of familial uveal melanomas are explained by a hereditary predisposition, implying the presence of as yet unknown hereditary predispositions. This hypothesis is reinforced by epidemiological ...
Eligibility Criteria
Inclusion
- Patient with a personal history of uveal melanoma (newly diagnosed, under treatment or in follow-up)
- Enrolled in or benefiting from a social security scheme
Exclusion
- Causal pathogenic variation identified in BAP1 or MBD4
- Patient does not consent to constitutional genetic analysis for diagnostic purposes
- Patient not consenting to a constitutional genetic analysis for research purposes
- Pregnant and breast-feeding women
- Patients under guardianship or trusteeship
Key Trial Info
Start Date :
October 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06550674
Start Date
October 29 2024
End Date
October 1 2027
Last Update
December 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Jean PERRIN
Clermont-Ferrand, Puy-de-Dôme, France, 63011